Sanofi: new approval for Sarclisa in China
(CercleFinance.com) - Sanofi announces that the Chinese NMPA has approved its Sarclisa, combined with bortezomib, lenalidomide and dexamethasone, for the treatment of newly diagnosed adult multiple myeloma ineligible for autologous stem cell transplantation.
This approval is motivated by the positive results of the IMROZ phase III study, which demonstrated that Sarclisa, in combination with this VRd regimen, significantly improved progression-free survival in these patients, compared with the VRd regimen alone.
Sarclisa thus becomes the first anti-CD38 approved in China in this indication. This is its second approval in the country in the space of three weeks, following that announced on 13 January for relapsed or refractory multiple myeloma.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
This approval is motivated by the positive results of the IMROZ phase III study, which demonstrated that Sarclisa, in combination with this VRd regimen, significantly improved progression-free survival in these patients, compared with the VRd regimen alone.
Sarclisa thus becomes the first anti-CD38 approved in China in this indication. This is its second approval in the country in the space of three weeks, following that announced on 13 January for relapsed or refractory multiple myeloma.
Copyright (c) 2025 CercleFinance.com. All rights reserved.